3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
5
Leukemia, Lymphocytic, Chronic, B-Cell
4
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma
3
Lymphoma, Large B-Cell, Diffuse
2
Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell
1
Interventions
Cyclophosphamide
14
fludarabine
8
Rituximab
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Vincristine
4
Doxorubicin
4
Dexamethasone
4
zanubrutinib
3
Prednisone
3
Nivolumab
3
Etoposide
3
tazemetostat
2
tafasitamab
2
pirtobrutinib
2
pembrolizumab
2
glofitamab
2
etoposide phosphate
2
cemiplimab
2
acalabrutinib
2
Leukapheresis
2
Immunotherapy, Adoptive
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cisplatin
2
Cell- and Tissue-Based Therapy
2
Biopsy
2
venetoclax
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Bendamustine Hydrochloride
×
30 days
×
Clear all
NCT07593482
2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2
Not yet recruiting
92 enrolled